Compassionate use of experimental therapies: who should decide?. Issue 10 (22nd July 2015)

• Record Type: Journal Article
• Authors: Zettler, Patricia J
• Is Part Of: EMBO molecular medicine. Volume 7:Issue 10(2015:Oct.)
• Page Start: 1248
• Page End: 1250
• Publication Date: 2015-07-22
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201505262
• Languages: English
• ISSNs: 1757-4676

Abstract

<abstract abstract-type="main" id="emmm201505262-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p content-type="executiveSummary">In addition to being an example of unsubstantiated hype about regenerative medicine, the controversy around the Italy‐based Stamina Foundation's unproven stem cell therapy represents another chapter in a continuing debate about how to balance patients' requests for early access to experimental medicines with requirements for demonstrating safety and effectiveness. Compassionate use of the Stamina therapy arguably should not have been permitted under Italy's laws, but public pressure was intense and judges ultimately granted access. One lesson from these events is that expert regulatory agencies may be the institutions most competent to make compassionate use decisions and that policies should include more specific criteria for authorizing compassionate use. But even where regulatory agencies make decisions based on clear rules, difficult questions will arise.</p> </abstract>